68 Followers on Owler
XBiotech is a biopharmaceutical company that develops antibody therapies for inflammatory diseases and colorectal cancer...
Read moreXBiotech is a biopharmaceutical company that develops antibody therapies for inflammatory diseases and colorectal cancer...
Read more
News
Nov 09, 2022
Owler
XBiotech, Inc.: XBiotech's revenue changed from $11.05M in Jun 2022 to $8.21M in Sep 2022
Oct 15, 2022
Pharmabiz
XBiotech: XBiotech begins patient enrolment in French National Cancer Institute sponsored phase I/II/III study for Natrunix therapy for colorectal cancer
Jun 20, 2022
FirstWord Pharma
XBiotech: XBiotech Announces Successful Completion of Phase I portion of Pancreatic Cancer Study
May 11, 2022
Associated Press News
XBiotech: XBiotech: Q1 Earnings Snapshot
May 10, 2022
Owler
XBiotech, Inc.: XBiotech's revenue changed from 18.39M in Dec 2021 to 14.04M in Mar 2022
Apr 28, 2022
FirstWord Pharma
XBiotech: XBiotech Announces French National Agency (ANSM) Approval and National Cancer Institute (INSA) funding to Support Phase I/II/III Clinical Study for Natrunix in Combination with Trifluridine/Tipiracil (TASKIN) for Treatment of Metastatic Colorectal Cancer
Feb 02, 2022
Seeking Alpha
XBiotech: XBiotech in antibody manufacturing deal with J&J unit Janssen
Feb 02, 2022
MarketScreener
XBiotech: XBiotech : Manufacturing Antibody Drug for Janssen Research & Development, LLC (Janssen), One of the Janssen Pharmaceutical Companies of Johnson & Johnson - Form 8-K
Jan 26, 2022
MarketScreener
XBiotech: XBiotech Announces First Patient Enrolled in Phase I Clinical Trial for Novel Arthritis Therapy Natrunix-SQ
Dec 13, 2021
FinanzNachrichten
XBiotech: XBiotech Inc.: FDA Approves XBiotech's IND in Rheumatology
XBiotech Competitors
1
2
3
4
5
6
7
8
9
10
Looking for similar companies to XBiotech?
XBiotech Quarterly and Annual Revenue
Trailing 12-Months Trend (TTM)
Annual Revenue
$8.2M
XBiotech's revenue is the ranked 10th among it's top 10 competitors. The top 10 competitors average 3.6B. Over the last four quarters, XBiotech's revenue has decreased by 62.7%. Specifically, in Q3 2022's revenue was $1.7M; in Q2 2022, it was $1.5M; in Q1 2022, it was $ < 1M; in Q4 2021, XBiotech's revenue was $4.5M.
XBiotech News
XBiotech Press Releases
XBiotech Videos
XBiotech Headquarters
XBiotech Summary
ABOUT
Overview
XBiotech is a biopharmaceutical company that develops antibody therapies for inflammatory diseases and colorectal cancer. XBiotech was founded in 2005. XBiotech's headquarters is located in Austin, Texas, USA 78744. XBiotech's Chairman & CEO, John Si...CEO
XBiotech's Chairman & CEO, John Simard, currently has an approval rating of 80%. XBiotech's primary competitors are XOMA, Aclaris & Elcelyx Therapeutics.Website
xbiotech.comCompetitors
View 15 XBiotech competitors here.Acquisitions
There have been no acquisitions found related to XBiotechInvestments
Recent investment data cannot be found related to XBiotechFrequently Asked Questions about XBiotech
When was XBiotech founded?
XBiotech was founded in 2005Who is XBiotech's CEO?
XBiotech's CEO is John SimardHow much revenue does XBiotech generate?
XBiotech generates $8.2M in revenueHow much funding does XBiotech have?
XBiotech has historically raised $76M in funding
Where is XBiotech's headquarters?
XBiotech's headquarters is in Austin Texas, USAHow many employees does XBiotech have?
XBiotech has 100 employeesWhat sector does XBiotech operate in?
XBiotech is in BiotechnologyWho are XBiotech's competitors?
XBiotech's top competitors are XOMA, Aclaris, Elcelyx Therapeutics